Targovax starts Phase Ib of ONCOS-102 in melanoma

Targovax A/S (OSE:TRVX) began the Phase Ib ONCOS C824 trial to evaluate ONCOS-102 plus Keytruda pembrolizumab in 12 patients with advanced or unresectable melanoma who have progressed despite prior treatment with Keytruda or Opdivo nivolumab.

The open-label, U.S. trial will evaluate 3 doses of 3x10¹¹ viral particles intratumoral ONCOS-102 on days 1, 4 and 8 preceded by cyclophosphamide for 3 days prior to the first ONCOS-102 dose. Patients will then receive Keytruda at week 3 and every 3 weeks for up to 24 weeks...